Samuel Okiror1*, Abraham Mulugeta2, Iheoma Onuekwusi3, Fiona Braka4, Sylvesta Malengemi5, John Burton6, Rustam Hydarav7, Brigitte Toure7, Bob Davis8, Carolyn Gathenji1, Chidiadi Nwogu1, Joseph Okeibunor9
1WHO Horn of Africa Coordination Office (HOA), Nairobi KENYA
2WHO, EMRO Amman
3WHO, Nairobi Kenya
4WHO Country Office, Nigeria
5WHO, Juba South Sudan
6UNHCR, Nairobi Kenya
7UNICEF, Nairobi Kenya
8American Red Cross, Nairobi Kenya
9WHO Regional Office for Africa (WHO AFRO)
There has been civil strife, spanning more than two decades in some countries and recurrent natural disasters in the Horn of Africa (HoA). This has consistently maintained these countries in chronic humanitarian conditions. More important however is the fact that these crises have also denied populations of these countries access to access to lifesaving health services. Children in the difficult terrains and security compromised areas are not given the required immunization services to build their immunity against infectious diseases like the poliovirus. This was the situation in 2013 when the large outbreaks of poliovirus occurred in the HoA. This article reviews the epidemiology, risk, and programme response to what is now famed as the 2013-204 poliovirus outbreaks in the HoA and highlights the challenges that the programme faced in interrupting poliovirus transmission here.
A case of acute flaccid paralysis (AFP) was defined as a child <15 years of age with sudden onset of fever and paralysis. Polio cases were defined as AFP cases with stool specimens positive for WPV.
Between 2013 and 2016, when transmission was interrupted 20,266 polio viruses were in the Horn of Africa region. In response to the outbreak, several supplementary immunization activities were conducted with oral polio vaccine (OPV) The trivalent OPV was used initially, followed subsequently by bivalent OPV, and targeting various age groups, including children aged <5 years, children aged <10 years, and individuals of any age. Other response activities were undertaken to supplement the immunization in controlling the outbreak. Some of these activities included the use of various communication strategies to create awareness, sensitize and mobilize the populations against poliovirus transmission.
The outbreaks were attributed to the existence of clusters of unvaccinated children due to inaccessibility to them by the health system, caused by poor geographical terrain and conflicts. The key lesson therefore is that the existence of populations with low immunity to infections will necessary constitutes breeding grounds for disease outbreak and of course reservoirs to the vectors. Though brought under reasonable control, the outbreaks indicate that the threat of large polio outbreaks resulting from poliovirus importation will remain constant unless polio transmission is interrupted in the remaining polio-endemic countries of the world.DOI: 10.29245/2578-3009/2021/S2.1104 View / Download Pdf
Samuel Okiror1*, Chidiadi Nwogu1, Obianuju Igweonu2, Rustam Hydarov3, Djiboui Karim4, Farkhard Imambakiev5, John Ogange6, Annet Kisakye7, Joseph Okeibunor8, Hemant Shukla9
1WHO Horn of Africa Coordination Office (HOA), Nairobi KENYA
2University of Nigeria, Nsukka
4WHO headquarters, Geneva
5UNICEF New York
6World Health Organization, Kenya Country Office
8WHO Regional Office for Africa (WHO AFRO) Brazzaville, Congo
9WHO Headquarters, Geneva
Poliovirus importations and related outbreaks occurred in the Horn of Africa (HoA) following an initial outbreak, which started in Somalia, spread into Kenya within ten days and later into Ethiopia and gradually to other countries in the region. National preparedness plans for responding to poliovirus introduction were insufficient in many countries of the Region. We describe a series of polio outbreak simulation exercises that were implemented to formally test polio outbreak preparedness plans in the HoA countries, as a step to interrupting further transmission.
The Polio Outbreak Simulation Exercises (POSEs) were designed and implemented. The results were evaluated and recommendations made. The roles of outbreak simulation exercises in maintaining regional polio-free status were assessed. In addition, we performed a comprehensive review of the national plans of all for seven countries in the HoA Region.
Seven simulation exercises, delivered between 2016 and 2017 revealed that participating countries were generally prepared for poliovirus introduction, but the level of preparedness needed improvement. The areas in particular need of strengthening were national preparedness plans, initial response, plans for securing vaccine supply, and communications.
Polio outbreak simulation exercises can be valuable tools to help maintain polio-free status and should be extended to other high-risk countries and subnational areas in the HoA Region and elsewhere. There is also need to standardize the process and methods for conducting POSE for comparability.DOI: 10.29245/2578-3009/2021/S2.1107 View / Download Pdf
Chidiadi Nwogu1*, Johnny Musyoka2, Carolyne Gathenji 1, Rosemary Nzunza4, Iheoma Onuekwusi3, Joseph Okeibunor5, Pascal Mkanda5, Hemant Shukla1, Shaikh Humayun Kabir1, Sam O Okiror1
11WHO Horn of Africa Coordination Office (HOA), Nairobi, Kenya
2Ministry of Health (MoH), Nairobi, Kenya
3WHO, Nairobi, Kenya
4Kenya Medical Research Institute (KEMRI), Nairobi, Kenya
5WHO Regional Office for Africa, Brazzaville, Congo
Globally, tremendous improvement has been made in Polio eradication since its inception in 1988. For the third time in a decade, Kenya has experienced a Polio outbreak along the border with Somalia. The affected areas were in Garissa County, replete with previous occurrences in 2006 and 2012. This article, give an account of series of events and activities that were used to stop the transmission within 13 weeks, an interval between the first and the last case of the 2013 outbreak.
In an attempt to stop further transmission and time bound closure of the outbreak, many activities were brought to fore: the known traditional methods, innovative approaches, improved finances and surge capacity. These assisted in case detection, implementation, and coordination of activities. The external outbreak assessments and the six-monthly technical advisory group recommendations were also employed.
There were increased case detections of >=2/100,000, stool adequacy >=80%, due to enhanced surveillance, timely feedbacks from laboratory investigation and diagnosis. Sustained coverage in supplemental immunisation of > 90%, ensured that immune profile of >=3 polio vaccine doses was quickly attained to protect the targeted population, prevent further polio infection and eventual reduction of cases coming up with paralysis.
Overall, the outbreak was stopped within the 120 days of the first case using 14 rounds of supplemental immunisation activities.DOI: 10.29245/2578-3009/2021/S2.1103 View / Download Pdf
Wolters ECh1, de Hoo K2, Kramer BW3, de Munter JPJM2,4
1Department of Neurology, UniversitatsSpital Zurich, Zurich, Switzerland
2Neuroplast BV, Urmond, The Netherlands
3Department of Paediatrics, Maastricht University Medical Centre, Maastricht, The Netherlands
4School for Mental Health and NeuroScience, Maastricht University, Maastricht, The Netherlands
A cytokine release syndrome (CRS), associated with elevated circulating levels of several cytokines including interleukin (IL)-6 and interferon (IFN)-γ, might be seen in some infectious insults, for instance in severe acute respiratory syndrome (SARS) induced by Coronavirus (Cov)-2, as well as following administration of natural and bispecific antibodies and, more recently, following adoptive T-cell therapies for cancer. Normally, inflammatory conditions activate the innate and adaptive immune systems, which results in the release of cytokines, responsible for the phagocytosis of apoptotic vesicles and resolution of inflammation. Pro-inflammatory cytokines such as IL-1β, tumor necrosis factor alpha (TNFα) and, especially in chronic inflammatory diseases, autoimmune diseases, cancer and cytokine storms, IL-6 play crucial roles in inflammation. In some instances, however, this release gets out of hand, and features of overzealous immune responses (macrophage activation syndromes) might occur, leading to cytokine release syndromes (CRS) with inflammatory signs such as fever, fatigue, nausea, and sometimes secondary organ dysfunction or multi-organ failure. Apart from specific vaccines and maybe the anti-viral remdesivir and/or dexamethasone for treatment of CRS, there are no convincing disease-modifying interventions. So far, though, non-antiviral and immune-targeted interventions, also affecting non-target cells, were found associated with many side effects. A more targeted or focused approach is thus needed. Pending the site of the CRS-inducing insult, CRSs may occur systemic or compartmental. Recently, preclinical research yielded a beneficial anti-inflammatory effect of fresh naive bone marrow-derived stem cells (bm-SCs) in the treatment of various compartmental CRSs in the immune-privileged central nervous system (CNS). Therefore, it is argued that bm-SCs might also play a disease-modifying role in the systemic CRS. Bm-SCs have the advantage of targeting only the cells of interest as they are very selective in their actions. In addition, they actively move to the sight of inflammation.DOI: 10.29245/2578-3009/2021/1.1205 View / Download Pdf
Priyanka Ray1, Noor Haideri2, Inamul Haque2, Omar Mohammed2, Saborni Chakraborty2, Snigdha Banerjee2,3#, Mohiuddin Quadir1#, Amanda E. Brinker 4,5, and Sushanta K. Banerjee2,3*
1Department of Coatings and Polymeric Materials, North Dakota State University, Fargo, ND
2Cancer Research Unit, VA Medical Center, Kansas City, MO
3Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS
4Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS
5Institute for Advancing Medical Innovation, University of Kansas Cancer Center, Kansas City, KS
Since the early days marking the first use of nanomedicine in the early 80s, there has been a meaningful change in the scientific field involving the Fabrication, characterization, and application of nanomaterials to treat many diseases, including cancers and genetic disorders. As unique and attractive properties of this novel class of materials unraveled, significant advances and discoveries were made over time. Addressing several challenges posed by conventional therapy, which were the only available treatment option for ailing patients, nanomedicine provided enhanced benefits, including reduced dosing, improved pharmacokinetics, and superior targeting efficiency. Several such formulations have successfully made their way to clinics and have shown promise in prolonging terminally ill patient populations' survival rates. However, the complex immune system and its various components, including various proteins and surface receptors, have made nanomaterials' journey from benchtop to the bedside a treacherous one. The innate and adaptive immune system interactions with nanomaterials are still under investigation and full of mysteries. This review highlights the various aspects of therapeutic nanocarriers and their current understanding of their immune systems' interactions.DOI: 10.29245/2578-3009/2021/1.1206 View / Download Pdf
Lisa M. James1,2,3, Rachel A. Johnson1, Scott M. Lewis1,4, Adam F. Carpenter1,4, Brian E. Engdahl1,2,5, Hollis E. Krug6,7, Apostolos P. Georgopoulos1,2,3,4*
1Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, 55417, USA
2Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA
3Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN 55455, USA
4Department of Neurology, University of Minnesota Medical School, Minneapolis, MN 55455, USA
5Department of Psychology, University of Minnesota Medical School, Minneapolis, MN 55455, USA
6Department of Rheumatology, Department of Veterans Affairs Health Care System, Minneapolis, MN, 55417, USA
7Department of Rheumatology, University of Minnesota Medical School, Minneapolis, MN 55455, USA
Mounting evidence suggests that autoimmune mechanisms may underlie the chronic symptoms characteristic of Gulf War Illness (GWI). The presence of antiphospholipid antibodies including Lupus Anticoagulant (LA) are often associated with autoimmune disorders. Here we evaluated and compared blood samples from veterans with GWI and veterans with other autoimmune conditions including relapsing remitting multiple sclerosis, rheumatoid arthritis, Sjögren’s syndrome, and lupus for the presence of LA using Silica Clotting Time and dilute Russell’s Viper Venom Time assays. Positive LA was identified in one-quarter of veterans with GWI; this proportion was not statistically different from the proportion of positive LA identified in patients diagnosed with the other autoimmune conditions. The present findings add to the literature implicating autoimmune mechanisms in GWI and point to the presence of prothrombotic antiphospholipid antibodies as a common contributing factor in GWI and other autoimmune disorders. Furthermore, activation of the coagulation system suggests new potential avenues for treatment for LA-positive Gulf War veterans.DOI: 10.29245/2578-3009/2021/1.1208 View / Download Pdf
Brandon C. Smith1,2 & Jessica L. Williams1*
1Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
2Department of Biological, Geological, and Environmental Sciences, Cleveland State University, Cleveland, OH, USA
Despite an increase in approved therapies for treating the inflammatory and neurodegenerative disease multiple sclerosis (MS), many of which have efficacy in the early, acute phases, there are no reliable treatments for the chronic, progressive stages of the disease. A deeper understanding of the biological underpinnings that govern differences between acute and chronic stages of MS and an animal model of MS, experimental autoimmune encephalomyelitis, will inform therapeutic development and personalized treatment strategies. It is well-known that the effects of inflammation are complex and the implications vary between stages. Complimentary to our recent publication, we will discuss here the pleiotropic effects of the cytokine interferonγ across disease states, along with the implications of downstream mechanisms of action.DOI: 10.29245/2578-3009/2021/1.1204 View / Download Pdf
Shinya Tanaka1*, Wataru Ise2, Yoshihiro Baba1, Tomohiro Kurosaki2,3#
1Division of Immunology and Genome Biology, Medical Institute of Bioregulation, Kyushu University, Higashi-ku, Fukuoka, 812-0054, Japan
2Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Suita, 565-0871,Japan
3Laboratory of Lymphocyte Differentiation, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, 230-0045, Japan
Gene expression must be strictly controlled during cell differentiation and function in mammalian systems. DNA methylation plays an important role in this process, and its pattern is shaped by balancing the activity of methyltransferases and demethylases. Ten-eleven translocation (TET) was identified as a demethylase that catalyzes the oxidation reaction of the methyl group of 5-methylcytosine (5mC), converting it to 5-hydroxymethylcytosine (5hmC). Recently, indispensable roles of TET proteins in the regulation of immune cells have been identified. Here, we review recent studies on the biological consequences of dysregulation of TET proteins in the immune system, with a particular focus on B cell biology. Finally, we discuss future perspectives in this research field.DOI: 10.29245/2578-3009/2021/1.1202 View / Download Pdf
Giovanna L. Gallo1*, Julieta S. Roldán2, Laura R. Delgui3,4
1Centro de Virología Animal (CEVAN)-CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas).
2Instituto de Investigaciones Biotecnológicas "Dr. Rodolfo A. Ugalde" (IIBIO), Universidad Nacional de San Martín (UNSAM) - CONICET, San Martín, Buenos Aires, Argentina.
3Instituto de Histología y Embriología de Mendoza (IHEM-CONICET). Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, CONICET, Mendoza, Argentina.
4Facultad de Ciencias Exactas y Naturales, Universidad Nacional de Cuyo, Mendoza, Argentina.
Mammarenavirus genus groups viruses causing human haemorrhagic diseases, including the New World (NW) Junín virus (JUNV), and the Old World (OW) viruses Lassa (LASV), among others. The high mortality and morbidity rates associated to pathogenic mammarenaviruses, the absence of vaccines and the constant threat of new emerging species, make these viruses a public health concern in endemic areas. Autophagy is a widely-known intracellular metabolic pathway involved in maintaining the cellular homeostasis in response to several stress conditions.DOI: 10.29245/2578-3009/2020/4.1197 View / Download Pdf
R. Christina Smith, MD1, Meera N. Patel2, Richard Sigmon, MD3, Niraj C. Patel, MD, MS1
1Division of Pediatrics, Division of Pediatric Infectious Disease and Immunology, Atrium Health, Charlotte, NC, USA
2North Carolina School of Science and Math
3Department of Internal Medicine, Division of Gastroenterology, Atrium Health, Charlotte, NC, USA
The licensed rotavirus vaccines are live attenuated and are a component of the routine U.S. childhood immunization schedule. Live vaccines administered to infants of mothers who received biologic response modifiers (BRM) during pregnancy can potentially cause serious vaccine-associated disease. The Advisory Committee on Immunization Practices (ACIP) recommends infants born to women who received BRM during pregnancy avoid live viral vaccines during the first year of life. There is a paucity of information regarding adverse events following inadvertent administration of live viral vaccines in these infants. We report three infants, born to mothers receiving infliximab during pregnancy, who tolerated multiple doses of rotavirus vaccine. Live viral vaccines may be safe in infants who were exposed to BRM in utero. Further studies are needed to support this observation, as this could affect current ACIP recommendations.DOI: 10.29245/2578-3009/2020/4.1195 View / Download Pdf
Anurag Singh1, Lakshya Gupta2, Vandana Gupta1*
1Department of Microbiology, Ram Lal Anand College, University of Delhi, Benito Juarez Road, New Delhi 110021, India
2Department of Computer Science and Engineering, Indian Institute of Technology, Varanasi, Uttar Pradesh 221005, India
The coronavirus disease (COVID-19) emerged in China in December 2019 and has since spread to over 188 countries affecting millions of individuals. Several reports in favour or against the heterologous protection conferred by the BCG vaccine against COVID-19 came up in the initial days of the pandemic and continue to do so. In this study, we compared the three worst-affected nations: The USA, India, and Brazil, their current pandemic scenario, and their respective national BCG immunization policies. USA recommends BCG vaccine only to a specific group of people and never had a national immunization scheme in place. Meanwhile, India introduced a nationwide scheme as early as 1948 and continues to endorse BCG immunization at birth. Brazil used the oral route to administer the BCG vaccine till 1976, and then shifted to intradermal injection. The correlation coefficient for the total number of cases, cases per million, the total number of deaths, deaths per million and case fatality rate ranges between 0.81-0.98. This indicates a very strong positive correlation in the various epidemiological parameters between countries with no national immunization scheme (USA) and countries with stringent national policies on BCG vaccination. The strongest correlation exists between the USA and Brazil followed by Brazil and India which is very closely followed by the USA and India. We found no consistent evidence to infer in favour of the hypothesis that BCG provides any non-specific protection against COVID-19.
BCG: Bacillus Calmette-Guérin
COVID-19: Coronavirus Disease 2019
DPT: Diphtheria, Pertussis, and Tetanus
HPV: Human Papillomavirus
HSV: Herpes Simplex Virus
ICTV: International Committee on Taxonomy of Viruses
OPV: Oral Poliovirus Vaccine
RSV: Respiratory Syncytial Virus
SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2
WHO: World Health OrganizationDOI: 10.29245/2578-3009/2020/4.1199 View / Download Pdf
Sara B. Intner1, Michelle Altrich2, Niraj C. Patel1
1Department of Pediatrics, Levine Children’s Hospital, Atrium Health, Charlotte, NC, USA
2Viracor Eurofins, Lee’s Summit, MO, USA
Measurement of pneumococcal antibody concentration is a frequently used parameter for functional antibody response to vaccination. Antibody concentration in response to vaccination and strength of antigen-antibody (avidity) interaction are both important measurements of functional antibody response. Both antibody concentration and avidity contribute to immunity against invasive pneumococcal disease. Higher avidity is correlated with increasing bactericidal activity and opsonophagocytosis. On the other hand, patients with lower pneumococcal avidity may be more likely to develop clinically significant pneumococcal sinopulmonary infections. Nine patients with recurrent bacterial respiratory infections were identified by retrospective chart review as having adequate pneumococcal antibody concentrations, but with low avidity for multiple serotypes following immunization with pneumococcal vaccine polyvalent (PPSV23). We assessed response with IgG replacement therapy in these patients. The mean number of serotypes with a normal antibody response (>1.3 𝛍g/ml) among 9 children following immunization with pneumococcal vaccine polyvalent was 19.1 (range 12-22) of 23 serotypes while the mean number of serotypes with a normal avidity response (≥1.0) was 4.7 (range 2-7) of 23 serotypes. Flow cytometry was performed for 8 of the 9 patients prior to starting SCIG replacement therapy. 100% of the cohort experienced a significant decrease in yearly infection rate after starting immunoglobulin replacement. This is the first study to assess the clinical response to immune globulin replacement in patients with normal pneumococcal antibody response but poor pneumococcal avidity, and suggests that patients with poor pneumococcal avidity but apparent normal response by pneumococcal antibody following PPSV23 may benefit from IgG replacement therapy.DOI: 10.29245/2578-3009/2020/4.1194 View / Download Pdf
DOI: 10.29245/2578-3009/2020/4.1201 View / Download Pdf
Lisa M. James1,2,3,4, Effie-Photini C. Tsilibary1,2, Spyros Charonis1,2, Apostolos P. Georgopoulos1,2,3,4*
1 Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA
2 Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA
3 Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA
4 Center for Cognitive Sciences, University of Minnesota, Minneapolis, MN, USA
Spyros S. Charonis 1,2, Effie-Photini Tsilibary 1,2, Apostolos P. Georgopoulos 1,2*
1Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN 55417, USA
2Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA
SARS-CoV-2 causes COVID-19, urgently requiring the development of effective vaccine(s). Much of current efforts focus on the SARS-CoV-2 spike-glycoprotein by identifying highly antigenic epitopes as good vaccine candidates. However, high antigenicity is not sufficient, since the activation of relevant T cells depends on the presence of the complex of the antigen with a suitably matching Human Leukocyte Antigen (HLA) Class II molecule, not the antigen alone: in the absence of such a match, even a highly antigenic epitope in vitro will not elicit antibody formation in vivo. Here we assessed systematically in silico the binding affinity of epitopes of the spike-glycoprotein to 66 common HLA-Class-II alleles (frequency ≥ 0.01). We used a sliding epitope window of 22-amino-acid-width to scan the entire protein and determined the binding affinity of each subsequence to each HLA allele. DPB1 had highest binding affinities, followed by DRB1 and DQB1. Higher binding affinities were concentrated in the initial part of the glycoprotein (S1-S460), with a peak at S223-S238. This region would be well suited for effective vaccine development by ensuring high probability for successful matching of the vaccine antigen from that region to a HLA Class II molecule for CD4+ T cell activation by the antigen-HLA molecule complex.DOI: 10.29245/2578-3009/2020/4.1198 View / Download Pdf
Ioanna Zerva, Vasileia Pateraki, Irene Athanassakis*
Department of Biology, University of Crete, Vassilika Vouton, Heraklion 70013, Crete, Greece
Effective and side-effect-free vaccines are still difficult tasks to achieve for a great majority of antigenic stimuli. Pathogen manipulation to abort infectivity and antigen delivery to ensure immune responsiveness are the major components vaccine technology tries to resolve. However, the development of an immune response is still a complicated matter, lies on hundreds of parameters and any effort towards activation can easily lead to adverse effects, making immunotherapy very difficult to control. The present review attempts to highlight the major parameters affecting immune responsiveness and show that vaccine technology, except from pathogen manipulation and the development of antigen delivery systems, requires attention to additional check-points. Analyzing the recently described personalized implantable vaccine technology, it becomes obvious that the nature of each antigenic stimulus dictates different responsiveness to the organism, which discourages the use of universal adjuvant and antigen-delivery systems. On the contrary, the ex vivo tuning of the immune response proposed by the implantable vaccine technology, allows controllable amendment of the response. The development of personalized technologies is expected to provide valuable tools for the management of human pathology.DOI: 10.29245/2578-3009/2020/4.1193 View / Download Pdf
Commanding Officer, Military Dental Centre (Gough Lines), Secunderabad, Telangana, Pin- 500015, India
Introduction: Establishing an accurate diagnosis and probable prognosis of ambiguous, extensive and destructive maxillary pathologies, is imperative for an appropriate, timely and effective treatment modality to be instituted. This is particularly true in the paediatric population, in order to ensure complete elimination of the lesion, with the least possible morbidity, debility, or interference with normal jaw growth.
Objectives: To assess the diagnostic and prognostic value of Immunohistochemistry (IHC) as an adjunct to Histopathological examination (HPE), in cases of destructive paediatric maxillary pathologies. To use the information thus obtained, to select the most ideal and efficacious management protocol for each case.
Material & Methods: An extensive study was carried out on 25 cases of destructive (as evidenced clinically and radiographically) maxillary lesions, in children of ages between 5 and 16 years. Positivity for an IHC tumor marker, namely Calretinin, was employed to distinguish maxillary cysts from tumors. In addition, Labelling indices of two IHC cell proliferation markers, namely Ki-67 and PCNA, indicated the proliferative activity of constituent cells of the pathologies, which aided in predicting their aggressive nature and recurrence potential. On the basis of the above information, the choice between a conservative versus radical treatment approach was made for each individual case.
Results & Conclusion: IHC proved to be of immense value as a diagnostic marker and a prognostic indicator in the paediatric maxillary pathologies. In addition to aiding the pathologist in making an accurate confirmatory diagnosis, it also served as an invaluable tool to the surgeon, in guiding the treatment plan by indicating the likely prognosis and chances of recurrence of these lesions.DOI: 10.29245/2578-3009/2020/4.1192 View / Download Pdf
Oluwatoyin Adenike Adeyemo-Salami
Department of Biochemistry, College of Medicine, University of Ibadan, Oyo State, Nigeria
Anything that affects the absorption of nutrients and intestinal function will invariably affect the physical well-being or the health status of an individual. Cystic fibrosis is a disease condition that is autosomal recessive and affects organs that have epithelia including the gastrointestinal tract of which the intestine is part, and is the one that is primarily affected. The major aberration responsible for it is mutations in the cystic fibrosis transmembrane conductance regulator gene. Phenotypical evidence of cystic fibrosis in the intestine includes obstruction, microbial dysbiosis, inflammation, acidity in the intestinal tract, malnutrition, immune dysfunction, intestinal dysmotility, appendiceal aberrations and intussusception. All these manifestations result in maldigestion and malabsorption of lipid, protein and carbohydrate in the intestine. The effect of cystic fibrosis on the digestion of certain micronutrients was also reported.
In this review, the pathophysiology, manifestations of cystic fibrosis in the gastrointestinal tract with emphasis on the small intestine, and the effects on digestion of macronutrients and micronutrients would be discussed.DOI: 10.29245/2578-3009/2020/3.1187 View / Download Pdf
Chandreyee Datta, Ashish Bhattacharjee*
Department of Biotechnology, National Institute of Technology, Durgapur, 713209, West Bengal, India.
Corona virus disease 2019 (COVID-19), is a viral disease caused by novel corona virus known as severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). The disease was declared as a pandemic by the World Health Organisation (WHO) on March 11, 2020. Initial studies have shown the molecular resemblances in the receptor binding domains of SARS-CoV and SARS-CoV-2 which bind angiotensin converting enzyme 2 (ACE 2) receptors and helps the virus to enter into the host cells to cause infection. Illness caused by COVID19 ranges from mild common cold to life threatening acute respiratory distress syndrome (ARDS), multi-organ dysfunction and shock. The key step in converting mild disease to severe is immune dysfunction and cytokine dysregulation resulting in “cytokine storm syndrome”. Clinical investigations in patients with COVID-19 have shown that a strong upregulation of cytokine and interferon production is common feature in SARS-CoV2-induced pneumonia, with an associated cytokine storm syndrome. Consequently, spotting of existing approved therapies with proper safety profiles to treat hyperinflammation is very essential in order to reduce COVID-19 associated mortality. Till date, no specific therapeutic drugs or vaccines are available to treat COVID-19. In this review, we intended to describe how cytokine storm is associated with the severity of COVID-19 disease and also tried to find out the best possible way to manage the hyperinflammatory response due to cytokine storm during COVID-19 infection using several interleukin receptor antagonists, inhibitors, intravenous immunoglobulins, cytokine adsorption device and repurposing of pre-existing antiviral and some antimalarial drugs etc.DOI: 10.29245/2578-3009/2020/3.1190 View / Download Pdf
DOI: 10.29245/2578-3009/2020/3.1191 View / Download Pdf
Nick F. Hallam1*, Janet A. Parker2
1Colposcopy Clinic, Women's Outpatients, Cumberland Infirmary, Carlisle, England, United Kingdom
2Manchester Cytology Centre, Division of Laboratory Medicine, Manchester University, NHS Foundation Trust, Manchester, England, United Kingdom
Malgorzata Kloc*1,2,3, Rafik M. Ghobrial1,2, Jacek Z Kubiak*4,5
1The Houston Methodist Research Institute, Houston, Texas 77030, USA
2The Houston Methodist Hospital, Department of Surgery, Houston, Texas, USA
3The University of Texas, M.D. Anderson Cancer Center, Department of Genetics, Houston Texas, USA
4Laboratory of Regenerative Medicine and Cell Biology, Military Institute of Hygiene and Epidemiology (WIHE), Warsaw, Poland
5UnivRennes, UMR 6290, CNRS, Institute of Genetics and Development of Rennes, Cell Cycle Group, Faculty of Medicine, Rennes, France
The interferons (IFNs) are the main antiviral immune factors. Currently, various IFNs therapies are used for the treatment of human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV), cancer, and autoimmune diseases. Recently, it has been suggested that IFN-α therapy should be used to lessen the respiratory symptoms in the SARS-CoV-2 virus- infected (COVID-19) patients. The SARS-CoV-2 enters the cells by binding to the Angiotensin-converting enzyme 2 (ACE2), which by recognizing the spike S1 protein of the virus, acts as a virus receptor. Because the expression of ACE2 is induced by IFN-α, the SARS-CoV-2 virus may exploit the anti-viral response by subverting the IFN functions to further its own propagation and infectability. We discuss here how the SARS-CoV-2 may also subvert the immune response of the lung macrophages, which also express ACE2, to exacerbate the severity of the COVID-19 respiratory symptoms.DOI: 10.29245/2578-3009/2020/2.1189 View / Download Pdf
Dana Khdr Sabir1*, Nabaz R. Khwarahm2, Shakhawan M. Ali3, Hayman J Abdoul4, Kochar I. Mahmood5, Rimantas Kodzius6,7*
1Department of Medical Laboratory Sciences, Charmo University, 46023 Chamchamal, Kurdistan Region, Iraq
2Department of Biology, College of Education, University of Sulaimani, Sulaimani, Kurdistan Region, Iraq
3Department of Oral and Maxillofacial Surgery, School of Medicine, Faculty of Dentistry, University of Sulaimani,Sulaimani, Kurdistan Region, Iraq
4Department of Pharmaceutical Chemistry, Charmo University, 46023 Chamchamal, Kurdistan Region, Iraq
5Charmo Centre for Research, Training and Consultancy, Charmo University, 46023 Chamchamal, Kurdistan Region, Iraq
6Kaunas Technology University (KTU), 37164 Panevezys, Lithuania
7Ludwig Maximilian University of Munich (LMU), 80539 Munich, Germany
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is a novel strain of coronavirus that is recently identified as an etiological agent for the current pandemic respiratory illness called coronavirus disease 2019 (COVID-19). The disease might have a zoonotic origin and has infected > 19 million people around the globe with > 700,000 deaths. The published data indicate that children are generally less susceptible to contracting COVID-19. Here, we are providing a review on current hypotheses that have tried to explain the low mortality and morbidity rate among children. We believe that understanding the immunological base of children’s protection can prevent further spread of the disease.DOI: 10.29245/2578-3009/2020/2.1188 View / Download Pdf
Paola Roxana Lev1,2, Nora Paula Goette1, Rosana Fernanda Marta1,2*
1Institute of Medical Research A. Lanari, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina
2Department of Hematology Research, Institute of Medical Research (IDIM), National Scientific and Technical Research Council (CONICET), University of Buenos Aires, Buenos Aires, Argentina
Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by the decrease in peripheral blood platelet count below 100 x 109/L, and an increased bleeding risk when thrombocytopenia drops below 30 x 109/L. The mechanisms leading to ITP in adults, although not completely elucidated, involves an imbalance between effector and regulatory cells that results in a breakdown of the immune tolerance. Autoantibodies are considered the main responsible for thrombocytopenia, although direct T-cell cytotoxic effect and lysis by Complement attachment and activation could also contribute to platelet elimination from circulation. In addition to increased peripheral clearance, abnormalities in platelet production also favors platelet count reduction. This review is intended to describe some specific knowledge about peripheral and bone marrow mechanisms leading to thrombocytopenia in adult ITP.DOI: 10.29245/2578-3009/2020/2.1185 View / Download Pdf
Rowland Utulu1*, Joseph Urang3, Aishat Usman1,2, Neni Aworabhi1, Ugochukwu Osigwe2, Muhammad Shakir Balogun1,2, Eniola A. Bamgboye4
1Nigeria Field Epidemiology and Laboratory Training Program
2African Field Epidemiology Network (AFENET), Abuja
3Rivers State Primary Healthcare Management Board, Port-Harcourt, Rivers state, Nigeria
4Department of epidemiology and medical statistics, faculty of public health, University of Ibadan, Nigeria
Background: WHO African region set a target for elimination of measles by 2020 and recommended member states adopt a case-based surveillance system. WHO AFRO guidelines for measles surveillance state that an optimally performing surveillance system is crucial to elimination of measles. Rivers State is one of the high burden states for measles in southern Nigeria.
Objective: This study assessed the performance of the measles case-based surveillance in Rivers state, Nigeria.
Methods: We reviewed measles case-based surveillance data in Rivers state, Nigeria from year 2011-2018.
Results: A total of 1,731 suspected cases were reported with 1,128 (65.2%) confirmed cases of measles. Majority were confirmed by epidemiologic linkage 907 (80.4%) while laboratory confirmed cases constituted 206 (18.3%). Age group 1-4 years was the most affected 443 (42.6%). For cases with vaccination status available 425 (53.1%) were unvaccinated. No discarded cases were reported from 2016 to 2018. Non-measles febrile rash illness rate target of ≥2 per 100,000 was not achieved at any point in the eight-year period. The proportion of districts/LGAs reporting >2 Non Measles-Non Rubella Febrile Rash Illness cases/year was above the minimum target of 80% in just four years.
Conclusion: The surveillance system performed poorly with sensitivity and representativeness less than optimal. Measles elimination must leverage upon existing structures for polio elimination to improve surveillance. A more detailed analysis of the system is essential to identify all the gaps that may retard elimination efforts.DOI: 10.29245/2578-3009/2020/1.1183 View / Download Pdf